The Phase 2 trial documented these side effects across all dose groups, and the data tells a clear story: most symptoms are gastrointestinal, most are mild to moderate, and most improve as the body adapts
NHS availability would require both MHRA approval and a positive NICE technology appraisal
Signs of serious allergic reactions, like facial swelling, hives, or difficulty breathing
New patients may end up picking a format without enough information
Theres also evidence from the Phase 2 trial data suggesting Retatrutide may favorably affect lean mass composition compared to bodyweight loss alone, though long-term Phase 3 data on this specific metric will be more definitive
Calibrate price varies by membership tier and treatment phase, typically ranging from several hundred to over a thousand dollars monthly